Litigation Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

Docket		Date Filed	2015-04-27
Court	District Court, S.D. New York	Date Terminated
Cause	15:1 Antitrust Litigation (Monopolizing Trade)	Assigned To	Ronnie Abrams
Jury Demand	Plaintiff	Referred To	Stewart D. Aaron
Patents	6,150,383; 6,150,384; 6,166,042; 6,166,043; 6,172,090; 6,211,205; 6,271,243; 6,303,640; 6,329,404
Link to Docket	External link to docket

Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-04-27	1		Patent No. Issue Date Patent Expiry 6,150,383 (the…its patent information that the two patents—United States Patent Nos. 5,965,584 (the “’584 Patent”) and…manufacturer’s patents and patent information for accuracy or trustworthiness. In listing patents and patent information…the ’777 Patent, the ’584 Patent, and the ’404 Patent, Takeda submitted eight other patents to the FDA…the ’584 Patent and the ’404 Patent as drug product patents claiming ACTOS only if the patents in fact	External link to document
2019-10-08	131	Memorandum & Opinion	two other patents-U.S. Patent Nos. 5,965,584 (the "'584 patent") and 6,329,404 (the "… several patents related to its diabetes medicines. The first of those patents, U.S. Patent. No. 4,687,777…hereinafter, "the Patents") as both drug product patents and method-of-use patents-and improperly … Normally, inventors obtain patents for their brand-name drugs. Patents that protect a drug may include…such patents must be submitted with an NDA is at the heart of this case. For each patent that	External link to document
2016-01-06	54		Patent No. Issue Date Patent Expiry 6,150,383 (the…listed three additional patents – the ’042 Patent, the ’043 Patent, and the ’090 Patent – as applicable method-of-use…Takeda asserted in its patent information that the two patents – United States Patent Nos. 5,965,584 (the…misleading patent information regarding the ’584 Met Combo Patent and ’404 Insulin Combo Patent for ACTOS… drug substance patent – U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) – expired on January	External link to document
2016-01-07	55		Patent No. Issue Date Patent Expiry 6,150,383 (the…listed three additional patents – the ’042 Patent, the ’043 Patent, and the ’090 Patent – as applicable method-of-use…Takeda asserted in its patent information that the two patents – United States Patent Nos. 5,965,584 (the…misleading patent information regarding the ’584 Met Combo Patent and ’404 Insulin Combo Patent for ACTOS… drug substance patent – U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) – expired on January	External link to document
2016-01-27	62		medications: U.S. Patent Nos. 5,965,584 (“’584 patent”) and 6,329,404 (“’404 patent”), both of which …U.S. Patent No. 4,687,777 (“’777 patent”), which expired in January 2011. Id. ¶ 158. Two patents claim…traditional patent settlement, Teva (the alleged patent infringer) agreed to pay Takeda (the patent holder… the underlying patent infringement cases, or (2) the supposed weakness of the patent claims would have…relating to the ACTOS and ACTOplus met patent litigations and patent settlements are no different from those	External link to document
2016-01-27	65		’584 patent at 18:19-21, 18:65-67 (claims 4 and 10). Takeda received U.S. Patent No. 6,329,404, which…pioglitazone patents, including the ’777, ’584, and ’404 patents, as well as the method-of-use patents, for … and ’404 patents only as “method- of-use” patents for ACTOS and never as “product” patents, as shown…Takeda had not described the patents as “product” patents in its patent submission letters to the FDA…to list a patent. For each patent, pioneer drug companies are required to submit the patent if and only	External link to document